Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GALR1 | P47211 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096234 | 0.97 | HTT (0.48) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL2095015 | 0.97 | HTT (0.48) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL346890 | 0.97 | HTT (0.48) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL2094841 | 0.95 | ESR2 (0.47) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL2094892 | 0.89 | ESR2 (0.46) | HDAC8HDAC6HDAC1ESR2NOTUM | |
| SCHEMBL781509 | 0.86 | HDAC1 (0.54) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL6275125 | 0.83 | HDAC8 (0.52) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL5147779 | 0.83 | ESR2 (0.54) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL42782 | 0.83 | HDAC8 (0.52) | HDAC8HDAC6HDAC1HTTLMNA | |
| SCHEMBL15260520 | 0.83 | HDAC8 (0.52) | HDAC8HDAC6HDAC1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | BARTA THOMAS E | 2006-04-20 | — | — | US | claimed |
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | claimed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | claimed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | claimed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | claimed |
| JP-2002537378-A | — | — | 2002-11-05 | — | — | JP | claimed |
| EP-1230219-A1 | AROMATIC SULFONS HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. Searle & Co. (US) | 2002-08-14 | — | — | EP | claimed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | claimed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | claimed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | claimed |
| WO-2000050396-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-31 | — | — | WO | claimed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-0023991-B1 | STYRYL DYESTUFFS, THEIR PREPARATION AND THEIR USE IN DYEING PAPER IN PARTICULAR | BAYER AG (DE) | 1983-07-27 | — | — | EP | disclosed |
| US-4366314-A | STYRYL DYE | BAYER AKTIENGESELLSCHAFT (DE) | 1982-12-28 | — | — | US | disclosed |
| EP-0037491-A2 | Dimethinic dyestuffs, their preparation and their use in dyeing synthetic and natural materials | BAYER AG (DE) | 1981-10-14 | — | — | EP | disclosed |
| EP-0023991-A1 | Styryl dyestuffs, their preparation and their use in dyeing paper in particular | BAYER AG (DE) | 1981-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HDAC8 1199/4885HDAC6 901/4885HDAC1 280/4885 |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP10 | HDAC8 148/4885HDAC6 193/4885HDAC1 102/4885 |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP3 | HDAC8 210/4885HDAC6 231/4885HDAC1 57/4885 |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | HDAC8 148/4885HDAC6 193/4885HDAC1 102/4885 |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP1, MMP13 | HDAC8 202/4885HDAC6 204/4885HDAC1 49/4885 |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | HDAC8 148/4885HDAC6 193/4885HDAC1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.